FDA approves Amneal’s generic potassium chloride
Amneal Pharmaceuticals has received the green light from the Food and Drug Administration for a generic version of potassium chloride oral solution, in dosage strengths of 20 meq per 15 ml and 40 meq per 15 ml.
"More than half of the volume we see for this product is in the institutional and long-term care segments," said Amneal executive vice president of sales and marketing Andy Boyer. "This indicates its usefulness in settings that treat patients who either require or prefer this oral liquid form."
Potassium chloride oral solution had a market value of approximately $185 million for the 12 months ending May 2018, according to IQVIA data.
"More than half of the volume we see for this product is in the institutional and long-term care segments," said Amneal executive vice president of sales and marketing Andy Boyer. "This indicates its usefulness in settings that treat patients who either require or prefer this oral liquid form."
Potassium chloride oral solution had a market value of approximately $185 million for the 12 months ending May 2018, according to IQVIA data.